SB-200646A

N/A

Report date: 2022/08/24 20:00:31

Base Information

Drug NameSB-200646A
Drug Alias NameSB-200646
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2b (5-HT2b) receptor antagonistsSerotonin 2c (5-HT2c) receptor antagonists
TargetsSerotonin 2c (5-HT2c) receptorSerotonin 2b (5-HT2b) receptor
Therapy Area/IndicationsDepressive Disorder, MajorFeeding and Eating DisordersObsessive-Compulsive Disorder +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsDepressive Disorder, MajorFeeding and Eating DisordersObsessive-Compulsive Disorder +[5] 

Other Information

ATC CodeN/A
Related LinksN/A